Obesity Drug Approvals Foretell A Less Cautious FDA

Law360, New York (July 19, 2012, 9:23 PM EDT) -- The U.S. Food and Drug Administration's approval of two weight-loss drugs in less than a month — 13 years after the last such approval — signals that the FDA is willing to tolerate more risk, after years of what industry critics say was an over-cautious approach that kept good drugs off the market.

On Tuesday, the FDA approved Vivus Inc.'s Qsymia, about three weeks after approving Belviq, a drug made by Arena Pharmaceuticals GmbH. Both drugs, which work in different ways to suppress hunger, are approved...
To view the full article, register now.